SK10892001A3 - Spôsob prípravy antibiotickej kyseliny pseudomonovej A mikrobiologickou cestou - Google Patents

Spôsob prípravy antibiotickej kyseliny pseudomonovej A mikrobiologickou cestou Download PDF

Info

Publication number: SK10892001A3
Authority: SK; Slovakia
Prior art keywords: pseudomonas; acid; pseudomonic acid; strain; hungary
Prior art date: 1999-02-03

Application number

SK1089-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Valeria Szell

Ildiko Lang

Istvan Barta

Anik Tegdes

Karoly Albrecht

Nee Suto Julianna Mozes

Istvan M. Szabo

Magdolna Petroczki

Janos Erdei

Eva Gulyas

Gabor Balogh

Original Assignee

Biogal Gy�Gyszergy�R Rt.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-03

Filing date

2000-02-03

Publication date

2002-06-04

2000-02-03 Application filed by Biogal Gy�Gyszergy�R Rt. filed Critical Biogal Gy�Gyszergy�R Rt.

2002-06-04 Publication of SK10892001A3 publication Critical patent/SK10892001A3/sk

Links

MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 title claims abstract description 39
MINDHVHHQZYEEK-HBBNESRFSA-N mupirocin Chemical compound C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-HBBNESRFSA-N 0.000 title claims abstract description 38
238000000034 method Methods 0.000 title claims abstract description 16
238000002360 preparation method Methods 0.000 title claims abstract description 4
230000008569 process Effects 0.000 title claims description 5
230000003115 biocidal effect Effects 0.000 title description 10
239000003242 anti bacterial agent Substances 0.000 title description 6
238000013048 microbiological method Methods 0.000 title description 3
241000589516 Pseudomonas Species 0.000 claims abstract description 27
238000000855 fermentation Methods 0.000 claims abstract description 13
230000004151 fermentation Effects 0.000 claims abstract description 13
241000589774 Pseudomonas sp. Species 0.000 claims abstract description 11
244000005700 microbiome Species 0.000 claims abstract description 11
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 7
230000015572 biosynthetic process Effects 0.000 claims abstract description 7
229910052799 carbon Inorganic materials 0.000 claims abstract description 7
229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
239000011707 mineral Substances 0.000 claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract description 6
125000001477 organic nitrogen group Chemical group 0.000 claims abstract description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 11
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
239000008103 glucose Substances 0.000 claims description 8
235000002639 sodium chloride Nutrition 0.000 claims description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
235000019486 Sunflower oil Nutrition 0.000 claims description 5
240000008042 Zea mays Species 0.000 claims description 5
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 5
235000002017 Zea mays subsp mays Nutrition 0.000 claims description 5
238000005273 aeration Methods 0.000 claims description 5
235000005822 corn Nutrition 0.000 claims description 5
239000000284 extract Substances 0.000 claims description 5
235000010755 mineral Nutrition 0.000 claims description 5
239000002600 sunflower oil Substances 0.000 claims description 5
241000283690 Bos taurus Species 0.000 claims description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
235000010216 calcium carbonate Nutrition 0.000 claims description 4
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
239000001888 Peptone Substances 0.000 claims description 3
108010080698 Peptones Proteins 0.000 claims description 3
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
235000011130 ammonium sulphate Nutrition 0.000 claims description 3
239000005018 casein Substances 0.000 claims description 3
238000002803 maceration Methods 0.000 claims description 3
235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
235000019319 peptone Nutrition 0.000 claims description 3
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
239000011780 sodium chloride Substances 0.000 claims description 3
239000012138 yeast extract Substances 0.000 claims description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
229910021380 Manganese Chloride Inorganic materials 0.000 claims description 2
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
239000011575 calcium Substances 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
229940041514 candida albicans extract Drugs 0.000 claims description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
235000021240 caseins Nutrition 0.000 claims description 2
229910052802 copper Inorganic materials 0.000 claims description 2
239000010949 copper Substances 0.000 claims description 2
229910000365 copper sulfate Inorganic materials 0.000 claims description 2
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
239000011790 ferrous sulphate Substances 0.000 claims description 2
235000003891 ferrous sulphate Nutrition 0.000 claims description 2
229910052742 iron Inorganic materials 0.000 claims description 2
BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 2
229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 2
239000011777 magnesium Substances 0.000 claims description 2
229910052749 magnesium Inorganic materials 0.000 claims description 2
229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
235000019341 magnesium sulphate Nutrition 0.000 claims description 2
239000011565 manganese chloride Substances 0.000 claims description 2
235000002867 manganese chloride Nutrition 0.000 claims description 2
229940099607 manganese chloride Drugs 0.000 claims description 2
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
159000000001 potassium salts Chemical class 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
239000011701 zinc Substances 0.000 claims description 2
229910052725 zinc Inorganic materials 0.000 claims description 2
239000011592 zinc chloride Substances 0.000 claims description 2
235000005074 zinc chloride Nutrition 0.000 claims description 2
244000068988 Glycine max Species 0.000 claims 1
235000010469 Glycine max Nutrition 0.000 claims 1
239000012530 fluid Substances 0.000 claims 1
235000001727 glucose Nutrition 0.000 claims 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
235000011187 glycerol Nutrition 0.000 claims 1
238000002955 isolation Methods 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 abstract 1
239000002609 medium Substances 0.000 description 14
229960003128 mupirocin Drugs 0.000 description 13
229930194369 pseudomonic acid Natural products 0.000 description 11
239000000243 solution Substances 0.000 description 10
JGKQAKOVZJHZTF-LHSFDMIQSA-N 9-[(e)-3-methyl-4-[(2s,3r,4s,5r)-3,4,5-trihydroxy-5-[[(2s,3s)-3-[(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]but-2-enoyl]oxynonanoic acid Chemical compound C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@]1(O)[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)OC1 JGKQAKOVZJHZTF-LHSFDMIQSA-N 0.000 description 8
JGKQAKOVZJHZTF-LMLZBOKOSA-N Pseudomonic acid B Natural products O=C(OCCCCCCCCC(=O)O)/C=C(\C[C@H]1[C@H](O)[C@H](O)[C@@](O)(C[C@H]2[C@@H]([C@H]([C@@H](O)C)C)O2)CO1)/C JGKQAKOVZJHZTF-LMLZBOKOSA-N 0.000 description 8
230000001580 bacterial effect Effects 0.000 description 8
KKMHFUKZHJOMJL-ZDACLCLWSA-N (+)-Pseudomonic acid C Natural products O=C(OCCCCCCCCC(=O)O)/C=C(\C[C@H]1[C@@H](O)[C@H](O)[C@H](C/C=C/[C@H]([C@@H](O)C)C)CO1)/C KKMHFUKZHJOMJL-ZDACLCLWSA-N 0.000 description 6
KKMHFUKZHJOMJL-WZLBZGCNSA-N 9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[(e,4r,5s)-5-hydroxy-4-methylhex-2-enyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid Chemical compound C[C@H](O)[C@H](C)\C=C\C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O KKMHFUKZHJOMJL-WZLBZGCNSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
229920001817 Agar Polymers 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
KKMHFUKZHJOMJL-UHFFFAOYSA-N Pseudomonic acid C Natural products CC(O)C(C)C=CCC1COC(CC(C)=CC(=O)OCCCCCCCCC(O)=O)C(O)C1O KKMHFUKZHJOMJL-UHFFFAOYSA-N 0.000 description 6
239000008272 agar Substances 0.000 description 6
241000589540 Pseudomonas fluorescens Species 0.000 description 5
239000007788 liquid Substances 0.000 description 5
125000000896 monocarboxylic acid group Chemical group 0.000 description 5
238000012360 testing method Methods 0.000 description 5
241000191967 Staphylococcus aureus Species 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
230000003570 biosynthesizing effect Effects 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
238000000451 chemical ionisation Methods 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000001819 mass spectrum Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
230000003595 spectral effect Effects 0.000 description 3
238000002211 ultraviolet spectrum Methods 0.000 description 3
244000063299 Bacillus subtilis Species 0.000 description 2
235000014469 Bacillus subtilis Nutrition 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
241000168225 Pseudomonas alcaligenes Species 0.000 description 2
241000589755 Pseudomonas mendocina Species 0.000 description 2
241000589776 Pseudomonas putida Species 0.000 description 2
241000589614 Pseudomonas stutzeri Species 0.000 description 2
241000193998 Streptococcus pneumoniae Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
230000000694 effects Effects 0.000 description 2
229930187697 mupirocin Natural products 0.000 description 2
DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000012071 phase Substances 0.000 description 2
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
229940031000 streptococcus pneumoniae Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000589539 Brevundimonas diminuta Species 0.000 description 1
241000131418 Brevundimonas vesicularis Species 0.000 description 1
241000589513 Burkholderia cepacia Species 0.000 description 1
241001136175 Burkholderia pseudomallei Species 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
206010011409 Cross infection Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
206010021531 Impetigo Diseases 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
241001535042 Methylobacterium mesophilicum Species 0.000 description 1
241000202934 Mycoplasma pneumoniae Species 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
241001646398 Pseudomonas chlororaphis Species 0.000 description 1
241001645955 Pseudomonas chlororaphis subsp. aureofaciens Species 0.000 description 1
241001508466 Pseudomonas cichorii Species 0.000 description 1
241000589630 Pseudomonas pseudoalcaligenes Species 0.000 description 1
241000589615 Pseudomonas syringae Species 0.000 description 1
241001464820 Pseudomonas viridiflava Species 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000006311 Pyoderma Diseases 0.000 description 1
206010041925 Staphylococcal infections Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
239000000370 acceptor Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
PTOJXIKSKSASRB-UHFFFAOYSA-O candicine Chemical compound C[N+](C)(C)CCC1=CC=C(O)C=C1 PTOJXIKSKSASRB-UHFFFAOYSA-O 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
BXRRQHBNBXJZBQ-UHFFFAOYSA-L dichloromanganese;hydrate Chemical compound O.Cl[Mn]Cl BXRRQHBNBXJZBQ-UHFFFAOYSA-L 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002774 effect on peptide Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
LFCFXZHKDRJMNS-UHFFFAOYSA-L magnesium;sulfate;hydrate Chemical compound O.[Mg+2].[O-]S([O-])(=O)=O LFCFXZHKDRJMNS-UHFFFAOYSA-L 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
229960003085 meticillin Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
239000006916 nutrient agar Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
206010033072 otitis externa Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
238000011218 seed culture Methods 0.000 description 1
238000012807 shake-flask culturing Methods 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000013597 soy food Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
235000016804 zinc Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/38—Pseudomonas

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Virology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Materials By Optical Means (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

SK1089-2001A 1999-02-03 2000-02-03 Spôsob prípravy antibiotickej kyseliny pseudomonovej A mikrobiologickou cestou SK10892001A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11845799P	1999-02-03	1999-02-03
US13733499P	1999-06-03	1999-06-03
PCT/US2000/002880 WO2000046389A1 (en)	1999-02-03	2000-02-03	Process for the preparation of pseudomonic acid a antibiotic by microbiological method

Publications (1)

Publication Number	Publication Date
SK10892001A3 true SK10892001A3 (sk)	2002-06-04

Family

ID=26816383

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1089-2001A SK10892001A3 (sk)	1999-02-03	2000-02-03	Spôsob prípravy antibiotickej kyseliny pseudomonovej A mikrobiologickou cestou

Country Status (22)

Country	Link
US (3)	US6509177B1 (no)
EP (1)	EP1151131A4 (no)
JP (1)	JP2003515311A (no)
KR (1)	KR20010113674A (no)
CN (2)	CN1670217A (no)
AU (1)	AU762768B2 (no)
BG (1)	BG105776A (no)
BR (1)	BR0009179A (no)
CA (1)	CA2360865A1 (no)
CZ (1)	CZ20012724A3 (no)
HK (1)	HK1041903A1 (no)
HR (1)	HRP20010576A2 (no)
HU (1)	HUP0300363A2 (no)
IL (2)	IL144679A0 (no)
IS (1)	IS6028A (no)
MX (1)	MXPA01007806A (no)
NO (1)	NO20013791L (no)
PL (1)	PL358615A1 (no)
SK (1)	SK10892001A3 (no)
TR (1)	TR200102234T2 (no)
WO (1)	WO2000046389A1 (no)
YU (1)	YU55601A (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20010576A2 (en)	1999-02-03	2002-08-31	Biogal Gyogyszergyar	Process for the preparation of pseudomonic acid a antibiotic by microbiological method
AU2002345856A1 (en)	2001-06-21	2003-01-08	Biogal Gyogyszergyar Rt	Metabolic controlled fermentation process for pseudomonic acid production
DE20220885U1 (de) *	2001-12-28	2004-06-24	BIOGAL Gyógyszergyár Rt.	Kristallines und amorphes Mupirocin-Calcium
IL150907A (en) *	2002-07-25	2007-07-04	Stephan Cherkez	Process for the preparation of stable amorphous calcium pseudomonate
KR20060123772A (ko)	2004-06-01	2006-12-04	테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그	약물의 비결정형의 제조 방법
US7619102B2 (en)	2005-02-21	2009-11-17	Axellia Pharmaceuticals Aps	Purification of mupirocin
WO2009117310A2 (en) *	2008-03-17	2009-09-24	Cedars-Sinai Medical Center	Methods for treatment and prevention of mrsa/mssa
CN104370896A (zh) *	2013-11-29	2015-02-25	江苏汉邦科技有限公司	一种纯化假单孢菌素的方法
CN103820369B (zh) *	2014-03-07	2015-11-18	浙江瑞邦药业有限公司	一种萤光假单胞菌及其应用
CN111918960B (zh)	2017-12-05	2025-01-28	比奥普来克斯有限公司	预防微生物感染的方法和组合物
CN108277243B (zh) *	2018-01-19	2021-03-12	浙江瑞邦药业股份有限公司	一种假单胞菌酸a的制备方法
CN108949845B (zh) *	2018-08-08	2021-08-10	福建康鸿生物科技有限公司	一种发酵培养基及由发酵培养基制备莫匹罗星的方法
US20240043888A1 (en)	2021-02-07	2024-02-08	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	Fermentation method for mupirocin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1643240A1 (de) *	1966-09-16	1971-06-24	Boehringer Sohn Ingelheim	Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane
US4071536A (en) *	1971-06-12	1978-01-31	Beecham Group Limited	Antibiotics
GB1395907A (en)	1971-06-12	1975-05-29	Beecham Group Ltd	Antibiotics
US3977943A (en)	1971-06-12	1976-08-31	Beecham Group Limited	Antibiotics
JPS5270083A (en) *	1975-12-04	1977-06-10	Yoshitomi Pharmaceut Ind Ltd	Manufacture of an antibiotics, trans-pseudomonic acid
GB1577730A (en)	1976-10-23	1980-10-29	Beecham Group Ltd	Treatment of infections with pseudomonicacid salts or esters thereof
GB1577545A (en)	1977-07-27	1980-10-22	Beecham Group Ltd	Treatment of swine dysenter
CA1103264A (en) *	1977-09-30	1981-06-16	Norman H. Rogers	Purification of pseudomonic acid
CA1115699A (en)	1978-05-20	1982-01-05	Alan D. Curzons	Lithium pseudomonate and its preparation
CA1196284A (en) *	1982-05-28	1985-11-05	Joshua Oduro-Yeboah	Pharmaceutical formulations
GB8415579D0 (en) *	1984-06-19	1984-07-25	Beecham Group Plc	Compounds
GB8428952D0 (en)	1984-11-16	1984-12-27	Beecham Group Plc	Formulations
GB8530796D0 (en)	1985-12-13	1986-01-22	Beecham Group Plc	Pharmaceutical composition
IE59628B1 (en)	1986-06-26	1994-03-09	Beecham Group Plc	Treatment of fungal infections
IN171883B (no)	1990-07-27	1993-01-30	Hoechst India
US5594026A (en) *	1990-12-11	1997-01-14	Smithkline Beecham Group P.L.C.	Polymorphs of crystalline mupirocin
US5292892A (en)	1991-05-07	1994-03-08	Sankyo Company, Limited	Anti-bacterial compound and pharmaceutical compositions thereof
US6503881B2 (en) *	1996-08-21	2003-01-07	Micrologix Biotech Inc.	Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
CA2267248A1 (en) *	1996-10-01	1998-04-09	Smithkline Beecham P.L.C.	Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms
US6231875B1 (en) *	1998-03-31	2001-05-15	Johnson & Johnson Consumer Companies, Inc.	Acidified composition for topical treatment of nail and skin conditions
HRP20010570A2 (en)	1999-02-03	2002-08-31	Biogal Gyogyszergyar	Process for the isolation of pseudomonic acid a from pseudomonic acid complex-containing culture broth
HRP20010576A2 (en)	1999-02-03	2002-08-31	Biogal Gyogyszergyar	Process for the preparation of pseudomonic acid a antibiotic by microbiological method
US6335023B1 (en) *	1999-06-30	2002-01-01	Ruey J. Yu	Oligosaccharide aldonic acids and their topical use
US6528086B2 (en) *	1999-09-28	2003-03-04	Zars, Inc.	Methods and apparatus for drug delivery involving phase changing formulations
IL137363A (en) *	2000-07-18	2005-12-18	Agis Ind 1983 Ltd	Pharmaceutical compositions containing mupirocin
IL150907A (en)	2002-07-25	2007-07-04	Stephan Cherkez	Process for the preparation of stable amorphous calcium pseudomonate

2000
- 2000-02-03 HR HR20010576A patent/HRP20010576A2/hr not_active Application Discontinuation
- 2000-02-03 CN CNA2005100056737A patent/CN1670217A/zh active Pending
- 2000-02-03 CA CA002360865A patent/CA2360865A1/en not_active Abandoned
- 2000-02-03 US US09/497,807 patent/US6509177B1/en not_active Expired - Fee Related
- 2000-02-03 PL PL00358615A patent/PL358615A1/xx not_active Application Discontinuation
- 2000-02-03 CZ CZ20012724A patent/CZ20012724A3/cs unknown
- 2000-02-03 YU YU55601A patent/YU55601A/sh unknown
- 2000-02-03 BR BR0009179-0A patent/BR0009179A/pt not_active IP Right Cessation
- 2000-02-03 CN CNB008058784A patent/CN1203184C/zh not_active Expired - Fee Related
- 2000-02-03 KR KR1020017009825A patent/KR20010113674A/ko not_active Ceased
- 2000-02-03 SK SK1089-2001A patent/SK10892001A3/sk unknown
- 2000-02-03 AU AU29808/00A patent/AU762768B2/en not_active Ceased
- 2000-02-03 TR TR2001/02234T patent/TR200102234T2/xx unknown
- 2000-02-03 JP JP2000597448A patent/JP2003515311A/ja not_active Ceased
- 2000-02-03 EP EP00908473A patent/EP1151131A4/en not_active Withdrawn
- 2000-02-03 HU HU0300363A patent/HUP0300363A2/hu unknown
- 2000-02-03 IL IL14467900A patent/IL144679A0/xx active IP Right Grant
- 2000-02-03 HK HK02103290.9A patent/HK1041903A1/zh unknown
- 2000-02-03 MX MXPA01007806A patent/MXPA01007806A/es not_active Application Discontinuation
- 2000-02-03 WO PCT/US2000/002880 patent/WO2000046389A1/en not_active Ceased
2001
- 2001-07-31 IS IS6028A patent/IS6028A/is unknown
- 2001-08-01 IL IL144679A patent/IL144679A/en not_active IP Right Cessation
- 2001-08-02 NO NO20013791A patent/NO20013791L/no not_active Application Discontinuation
- 2001-08-03 BG BG105776A patent/BG105776A/xx unknown
- 2001-10-11 US US09/975,796 patent/US6506591B2/en not_active Expired - Fee Related
2002
- 2002-11-12 US US10/293,675 patent/US7078223B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1354798A (zh)	2002-06-19
TR200102234T2 (tr)	2002-10-21
US7078223B2 (en)	2006-07-18
JP2003515311A (ja)	2003-05-07
IS6028A (is)	2001-07-31
IL144679A (en)	2007-06-17
AU762768B2 (en)	2003-07-03
HRP20010576A2 (en)	2002-08-31
BG105776A (en)	2002-05-31
MXPA01007806A (es)	2003-06-04
AU2980800A (en)	2000-08-25
NO20013791L (no)	2001-10-02
PL358615A1 (en)	2004-08-09
CZ20012724A3 (cs)	2001-12-12
EP1151131A4 (en)	2004-05-12
YU55601A (sh)	2003-02-28
CN1203184C (zh)	2005-05-25
WO2000046389A1 (en)	2000-08-10
KR20010113674A (ko)	2001-12-28
NO20013791D0 (no)	2001-08-02
EP1151131A1 (en)	2001-11-07
US20020042103A1 (en)	2002-04-11
CN1670217A (zh)	2005-09-21
US6509177B1 (en)	2003-01-21
HUP0300363A2 (hu)	2004-06-28
HK1041903A1 (zh)	2002-07-26
US20030100083A1 (en)	2003-05-29
WO2000046389A9 (en)	2001-09-07
IL144679A0 (en)	2002-06-30
CA2360865A1 (en)	2000-08-10
BR0009179A (pt)	2001-11-27
US6506591B2 (en)	2003-01-14

Publication	Publication Date	Title
Singh et al.	2009	Optimisation of process parameters for growth and bioactive metabolite produced by a salt-tolerant and alkaliphilic actinomycete, Streptomyces tanashiensis strain A2D
Patel et al.	2014	Indole-3-acetic acid (IAA) production by endophytic bacteria isolated from saline dessert, the little Runn of Kutch
SK10892001A3 (sk)	2002-06-04	Spôsob prípravy antibiotickej kyseliny pseudomonovej A mikrobiologickou cestou
Sarkar et al.	2008	Enhanced production of antimicrobial compounds by three salt-tolerant actinobacterial strains isolated from the Sundarbans in a niche-mimic bioreactor
TANAKA et al.	1993	PHTHOXAZOLIN A, A SPECIFIC INHIBITOR OF CELLULOSE BIOSYNTHESIS FROM MICROBIAL ORIGIN I. DISCOVERY, TAXONOMY OF PRODUCING MICROORGANISM, FERMENTATION, AND BIOLOGICAL ACTIVITY
Harikrishnan et al.	2016	Enhanced production of phenazine‐like metabolite produced by Streptomyces aurantiogriseus VSMGT1014 against rice pathogen, Rhizoctonia solani
JP4521145B2 (ja)	2010-08-11	抗生物質カプラザマイシン類およびその製造法
US7202063B1 (en)	2007-04-10	Processes for the production of rhamnolipids
Technikova-Dobrova et al.	2004	Design of mineral medium for growth of Actinomadura sp. ATCC 39727, producer of the glycopeptide A40926: effects of calcium ions and nitrogen sources
Lahoum et al.	2016	Antifungal activity of a Saharan strain of Actinomadura sp. ACD1 against toxigenic fungi and other pathogenic microorganisms
Hernandez et al.	2000	N-acetyl-γ-hydroxyvaline lactone, an unusual amino acid derivative from a marine streptomycete
Wang et al.	2006	Bioactive hydroxyphenylpyrrole-dicarboxylic acids from a new marine Halomonas sp.: Production and structure elucidation
Terano et al.	2002	Siderophore production and induction of iron-regulated proteins by a microorganism from rhizosphere of barley
Falzone et al.	2013	Development of a chemically defined medium for the production of the antibiotic platensimycin by S treptomyces platensis
Srividya et al.	2008	Study of the soil isolates for antimicrobial activity
Domzalski et al.	2021	Uncovering potential interspecies signaling factors in plant-derived mixed microbial culture
ZA200106171B (en)	2002-10-26	Process for the preparation of pseudomonic acid A antibiotic by microbiological method.
KR100411187B1 (ko)	2003-12-18	신규한 스트렙토마이세스 속 ｇ91353(ｋｃｔｃ18056ｐ)균주 및 신규 항세균제
JP5636179B2 (ja)	2014-12-03	新規化合物ウォークマイシン、その製造方法、及びその用途
WO1999024439A1 (en)	1999-05-20	Novel substance ft-0554 and process for producing the same
Biswas et al.	2011	Isolation and characterization of Streptomyces sp. ANBS-15 and antimicrobial activities of its secondary metabolites
Harikrishnan et al.	2015	Enhanced production of phenazine-like metabolite produced
Meena et al.	2004	Characterisation of rhizobacteria antagonistic to bacterial blight of rice from rhizosphere of basmati rice
MDM	0	Production of Ascorbic Acid by Acetobacter Species Isolated from Soil in Keffi, Nigeria
Vepritskaya et al.	2002	Selection of ergot alkaloid producers by induced mutagenesis